RELATION BETWEEN HIV-1 SYNCYTIUM INHIBITION ANTIBODIES AND CLINICAL OUTCOME IN CHILDREN | |
Article | |
关键词: HUMAN IMMUNODEFICIENCY VIRUS; ENVELOPE GLYCOPROTEIN; AIDS RETROVIRUS; HTLV-III; INVOLVEMENT; ASSOCIATION; RECEPTOR; ANTIGEN; FUSION; TYPE-1; | |
DOI : 10.1016/0140-6736(91)92660-T | |
来源: SCIE |
【 摘 要 】
Syncytium formation, a feature of HIV-1-induced cytopathology, allows the virus to propagate through cell-to-cell spread. An assay has been developed to measure antibodies (syncytium inhibition, SI) that inhibit this process. Two cell lines were used: the indicator cells, which are not HIV-1 infected, bear CD4 receptors on their surface; the fusogenic HIV-1 infected cells, which do not release virus but are responsible for initiating syncytium formation, are free of CD4 receptors. Co-cultivation of about 10(5) of each of these cells induces the emergence of 70-100 multinucleated giant cells within 48 h. Sera from 34 children born to HIV-1-infected mothers were tested by western blot (WB) and SI assay. SI antibodies were detected in the blood of 15 (65%) of 23 WB-positive children and in none of 11 WB-negative children. There were striking differences in prevalence and titre of SI antibodies in children with lymphocytic interstitial pneumonitis (LIP) compared with those with opportunistic infections (OI). All 8 children with LIP had SI antibodies ranging in titre from 40 to > 320. By contrast, only 2 of 7 with OI had SI antibodies, in both of whom the SI titre was 20 (p < 0.05). No sera from children who had seroreverted contained SI antibodies. The findings point to the need to identify the specific HIV-I peptides or epitopes responsible for syncytium formation since SI antibodies correlate with clinical outcome in children.
【 授权许可】
Free